This is a new shared resource established by the use of CCSG developmental funds following the recommendation of the Cancer Center Leadership Council and the endorsement of the External Advisory Committee. The Small Animal Imaging Core serves to provide imaging modalities such as computed tomography (CT), in vivo optical (bioluminescence and fluorescence), positron emission tomography (PET), quantitative autoradiography, and ultrasound imaging to USC Norris Comprehensive Cancer Center (NCCC) investigators. By providing investigators with over $1.6 million dollars of equipment, expertise in each modality through technicians with over 10 years of small animal imaging experience, and a newly renovated facility with active waste anesthetic gas delivery and stereotactic delivery of cells, investigators have access to equipment without concern for the operational costs involved (staff, service contracts, maintenance, repair, upgrade), which are usually prohibitive for any single investigator to bear. Primary users of this shared resource are NCCC investigators with peer-reviewed, funded projects. The users share in the mission to promote novel, translatable advances in cancer research through In vivo imaging of disease processes and development of new molecular therapeutics and biomarkers for diagnostics. In order to continue this course, the Core remains committed to provide state-of-the-art technologies to support researchers'needs. Currently, the Core supports a dynamic and diverse range of research and provides flexibility in development. The varied modalities in the Small Animal Imaging Core provide a means to monitor each investigators'disease of interest through novel techniques such as gene reporter systems, cell proliferation, angiogenesis, gene therapy, cell-cell interaction in roles of proliferation and metastatic development, androgen involvement in metastatic potential, gene expression in metastatic development, and diet restriction's involvement in increasing the therapeutic effect of chemotherapies. In addition, the modalities also provide a means to produce advanced experimental methods such as orthotopic models of cancer without surgery, monitoring of response through non-invasive means, and metrics using regions of interest (ROI) to monitor disease progression and therapeutic efficacy. As a result, the funding will allow for: 1) novel and current methods to be utilized by NCCC investigators;2) provide further opportunities to decrease costs; and 3) progress to a translational research setting with clinically relevant applications.

Public Health Relevance

Support of the Small Animal Imaging Core underscores the current work in cancer research by providing advanced technologies for translational applications. By allowing researchers to utilize novel techniques and technologies, in vivo imaging: 1) complements in vitro studies;2) decreases costs associated with animal research through successive longitudinal imaging and minimized operational costs; and 3) provides a translatable imaging method with direct clinical relevance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-38
Application #
8567474
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
38
Fiscal Year
2013
Total Cost
$92,671
Indirect Cost
$33,700
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications